Senate Panel Backs FDA Moves On Breast Implants

WASHINGTON (Reuters) - Senate investigators found no reason the U.S. Food and Drug Administration should reverse its conditional approval of silicone breast implants, according to findings released on Friday.

MORE ON THIS TOPIC